Document Detail


Cardiospecific sevoflurane treatment quenches inflammation but does not attenuate myocardial cell damage markers: a proof-of-concept study in patients undergoing mitral valve repair.
MedLine Citation:
PMID:  24595228     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: /st>Inflammation is considered a key mediator of complications after cardiac surgery. Sevoflurane has been shown to quench inflammation and to provide cardioprotection in preclinical studies. Clinical studies using sevoflurane confirm this effect on inflammation but do not consistently show clinical benefits. This paradox may indicate that the contribution of inflammation to postoperative sequalae is less than commonly thought or that systemic doses are too low in their local concentration. To test the latter, we evaluated the effects of intramyocardial sevoflurane delivery.
METHODS: /st>Selective myocardial sevoflurane delivery was performed during aortic cross-clamping in patients undergoing valve surgery (n=11).
RESULTS: were compared with a control group not receiving sevoflurane (n=10). A reference group (n=5) was added to evaluate the effects of systemic sevoflurane delivery. Paired arterial and myocardial venous blood samples were collected at various time points post-reperfusion. Inflammatory mediators and myocardial cell damage were studied.ResultsIntramyocardial delivery was superior to systemic delivery in attenuation of interleukin-6 and interleukin-8 (-44% and -25%, respectively; both P=0.001). Myocardial and systemic sevoflurane delivery effectively suppressed surgery-related inflammatory responses including postoperative C-reactive protein levels when compared with controls [63 (47-99) (P=0.01) and 58 (56-81) (P=0.04) compared with 107 (79-144) mg litre(-1)]. Sevoflurane treatment did not reduce postoperative troponin T, creatine kinase, and creatine kinase-MB values.
CONCLUSIONS: /st>This proof-of-concept study suggests that intramyocardial delivery compared with the systemic delivery of sevoflurane more strongly attenuates the systemic inflammatory response after cardiopulmonary bypass without reducing postoperative markers of myocardial cell damage.Clinical trial registrationNederlands Trial Register NTR2089.
Authors:
K A Kortekaas; A van der Baan; L P H J Aarts; M Palmen; C M Cobbaert; J C M Verhagen; F H M Engbers; R J M Klautz; J H N Lindeman
Related Documents :
2616408 - Cardiac tamponade complicating leukaemia: immediate chemotherapy or pericardiocentesis?
18984988 - Development of left ventricular apical akinesis and thrombus during pericardiocentesis ...
7143508 - The effect of dopamine on postburn myocardial depression.
23954318 - Pure agraphia in romaji after left inferior frontal gyrus infarction: a case of selecti...
11788418 - Muscle lim protein deficiency leads to alterations in passive ventricular mechanics.
15671608 - Prognostic value of i-123 metaiodobenzylguanidine imaging in vasospastic angina without...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-3-3
Journal Detail:
Title:  British journal of anaesthesia     Volume:  -     ISSN:  1471-6771     ISO Abbreviation:  Br J Anaesth     Publication Date:  2014 Mar 
Date Detail:
Created Date:  2014-3-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372541     Medline TA:  Br J Anaesth     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Repetitive transcranial magnetic stimulation for stroke rehabilitation-potential therapy or misplace...
Next Document:  Loss of photoreceptors results in upregulation of synaptic proteins in bipolar cells and amacrine ce...